Interview with Tomáš Matějovský, Partner, CMS Cameron McKenna Czech…
Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated…
Address: CMS Cameron McKenna v.o.s. Palladium, Na Poříčí 1079/3a 110 00 Prague 1,Czech Republic
Tel: +420 296 798-111
Web: http://www.cms-cmck.com/Prague-Czech-Republic
The Prague office of CMS was established in 1991. The office has over 35 international and local lawyers and provides a full range of legal services to both domestic and international clients. We conduct regular independent reviews with clients and these indicate that they value our ability to combine international expertise with local knowledge.
We have significant experience in working with international and local companies, insurers, banks and financial institutions, private organizations and government authorities. CMS in Prague is considered a market leader and our experts, such as Tomáš Matějovský, receive excellent feedback from clients.
CMS Cameron McKenna has a track record of advising lifesciences businesses throughout Central and Eastern Europe. We have been established in the region for more than twenty years, which means we never underestimate the differences between local markets, whilst taking into account EU and EEA standards.
Over the past years sector regulations in the region have undergone significant changes – from the rules on marketing pharmaceutical and healthcare products to legislation relating to medical devices. The changes have had a profound effect on the way business is conducted in CEE. We’ve made it our business to know the market inside out.
Our clients tell us that we have the in-depth knowledge they need to support their businesses across the region. We speak the industry’s language and our cross-regional lifesciences practice comprises 50+ lawyers advising some of the sector’s major players and representatives.
Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated…
Martin Mátl, executive director of the Czech Association of Pharmaceutical Companies (ČAFF), shares the key priorities and challenges of the association and its members; assesses the Czech generics ecosystem, and…
CzechBio’s Serhiy Forostyak, MD, Ph.D, shares the importance of a strong platform where all actors of the biotech landscape can develop their ideas and establish valuable partnerships on a national…
Despite being recently divested from multinational pharma giant Sanofi, Czech firm Zentiva is becoming one of the fastest-growing generics manufacturing companies in Europe, with a swathe of recent international acquisitions…
The Czech Republic is aiming to carve out a space for itself among Europe’s most innovative countries by 2030 as part of the ‘Innovation Strategy of the Czech Republic 2019–2030.’…
One of the very first former-communist European states to attain a successful economic transition, the Czech Republic today puts across a compelling argument for being regarded as one of the…
Entrepreneurially-minded individuals, together with academic institutions with their fingers on the pulses of the latest trends, are propelling Czech pharma companies to great success and cementing the Czech Republic at…
Novartis Czech Republic’s Heidrun Irschik explains the potentially game-changing ramifications of Big Data on the Czech pharmaceutical and healthcare industries. The opportunities offered by big data are present and…
The general manager of ALK Czech Republic and Slovakia on his strategy which led to success within the first one and a half years of ALK’s physical presence in the…
Reckitt Benckiser’s General Manager for the CEE region, Lajos Magyari, discusses the strength of the company’s current portfolio, the importance of innovation and the success factors he focuses on to…
The general manager of Wörwag Pharma Czech Republic & Slovakia reviews to what degree the Czech and Slovak market are homogeneous and which strategies can be successfully transferred from one…
There is frequent dialogue between the pharmaceutical industry, relevant regulatory authorities, and government stakeholders in the Czech Republic, but this dialogue is often strained. However, more frequent and constructive interaction between…
Women’s health is an increasingly significant niche for pharma companies operating in the Czech Republic, with large areas of unmet need and opportunities for growth. We have great expectations…
See our Cookie Privacy Policy Here